Litigation Details for ZS Pharma, Inc. v. Lupin Limited (D. Del. 2023)

ZS Pharma, Inc. v. Lupin Limited (D. Del. 2023)

Docket	1:23-cv-01189	Date Filed	2023-10-20
Court	District Court, D. Delaware	Date Terminated	2024-05-29
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	11,738,044
Link to Docket	External link to docket

Details for ZS Pharma, Inc. v. Lupin Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-10-20				External link to document

Litigation summary and analysis for: ZS Pharma, Inc. v. Lupin Limited (D. Del. 2023)

Last updated: July 18, 2026

ZS Pharma v. Lupin 1:23-cv-01189: Litigation Summary, Claims At Issue, and Patent-Strength Implications

ZS Pharma, Inc. is suing Lupin Limited in the U.S. District Court case captioned ZS Pharma, Inc. v. Lupin Limited, No. 1:23-cv-01189 (filed 2023). The docket number and caption identify a U.S. patent-infringement dispute tied to FDA product entry under the Hatch-Waxman framework, where the litigation posture typically turns on Orange Book-listed patents, claim construction, and whether the asserted patents are invalid, not infringed, or both.

However, without the publicly available docket content that specifies (1) the drug product and NDA/ANDA or reference listed drug, (2) the asserted patents and asserted claims, (3) the parties’ filings defining claim scope (complaint, infringement contentions, answers, PTAB stays), and (4) the case schedule and dispositions (Markman orders, motions to dismiss or summary judgment, trial dates, settlement terms), a complete and accurate litigation summary cannot be produced.

What is the status of ZS Pharma, Inc. v. Lupin Limited (1:23-cv-01189) and what happened procedurally?

Featured-snippet answer: No status resolution details can be stated accurately for 1:23-cv-01189 without the docket history (orders, filing dates, and case events).

Key procedural milestones that matter in Hatch-Waxman suits

• Complaint filing and asserted-patent identification
• Service and answer with defenses (noninfringement, invalidity, unenforceability)
• Early motions (Rule 12), venue, personal jurisdiction
• Markman claim construction briefing and order
• Discovery schedule and infringement/invalidity expert work
• Summary judgment or dismissal outcomes
• Trial setting or final disposition
• Any stay pending PTAB IPRs or related proceedings
• Settlement and dismissal with prejudice (if applicable)

Which patents and claims are asserted in ZS Pharma v. Lupin (1:23-cv-01189)?

Featured-snippet answer: The asserted patents and specific claims cannot be listed accurately from the case number and caption alone.

What a correct asserted-patents table must include

• Patent number(s)
• Patent owner/assignee(s)
• Publication status and claim categories (composition, formulation, method of use, manufacturing)
• Count of asserted claims per patent
• Parties’ infringement theory (literal vs doctrine of equivalents)
• Priority and prosecution-history relevant dates
• Whether the asserted patents are Orange Book-listed for the NDA/ANDA product

What is the infringement theory Lupin used in 1:23-cv-01189 and what are typical defenses?

Featured-snippet answer: Defense posture cannot be characterized reliably without the answer and responsive pleadings.

Typical Hatch-Waxman infringement/invalidity defenses in this posture

• Noninfringement: lack of element-by-element claim coverage in the ANDA product
• Invalidity: anticipation/obviousness (35 USC 102/103), lack of written description/enablement (35 USC 112)
• Indefiniteness or improper claim scope
• No statutory subject matter issues (rare, but can arise for method claims)
• Inequitable conduct or prosecution misconduct (if pled)
• Unenforceability defenses (inequitable conduct, patent misuse)

Is the dispute tied to ANDA Paragraph IV certifications, and which is the regulatory trigger?

Featured-snippet answer: The Paragraph IV regulatory trigger cannot be verified from the caption and case number alone.

How to map the litigation to the FDA record (what must be known)

• Reference listed drug (RLD)
• NDA number and label
• ANDA number (Lupin)
• Orange Book patent list for the RLD
• Whether the certification is Paragraph II, III, or IV
• Whether the litigation is for a generic entry, authorized generic, or a specific strength/dosage form

What does Orange Book status imply for the litigation leverage in ZS Pharma v. Lupin?

Featured-snippet answer: Orange Book-listed patent expiration and exclusivity status cannot be stated accurately without the RLD/NDA identity and the list of patents actually asserted in the case.

What to compute once the asserted patents are known

• Patent expiration date(s) and any pediatric exclusivity extensions
• Method-of-use patent expiration vs composition patent expiration
• Whether any exclusivity blocks generic approval irrespective of patent expiration
• Whether the case targets patents expiring near-term (greater settlement pressure)

How strong is the ZS Pharma patent estate in this case, based on the typical evaluation framework?

Featured-snippet answer: Patent strength cannot be assessed without the specific asserted patents and their claim sets.

Strength factors that drive outcomes in Hatch-Waxman cases

• Claim breadth and how construed against prior art
• Prior art landscape relevant to the asserted claims’ earliest priority
• Prosecution narrowing that limits equivalents
• Commercial necessity of design-around options
• Whether there are parallel IPRs affecting validity likelihood
• “Design-around feasibility” based on claim elements relevant to the accused ANDA formulation/process

What generic entry risks exist for Lupin if the case reaches claim construction or summary judgment?

Featured-snippet answer: Entry risk magnitude depends on which patents are asserted, which claims survive claim construction, and the remedies posture, none of which are available in the provided information.

Risk drivers that matter to launch timing

• Survival of at least one asserted claim for at least one asserted patent
• Claim construction decisions that narrow or broaden the alleged infringement footprint
• Whether Lupin can design around by changing formulation/process
• Whether a final judgment timing intersects with FDA approval schedules and tentative launch plans

Did Lupin challenge validity in PTAB IPRs, and how does that affect 1:23-cv-01189?

Featured-snippet answer: PTAB stay and IPR linkage cannot be determined without docket data showing IPR numbers, institution dates, and stay motions.

What would be necessary for an accurate PTAB-linked analysis

• IPR case number(s) filed by Lupin or co-defendants
• Patent owner responses
• Institution rulings and final written decision timing
• Whether the district court stayed the case under 35 USC § 316(a) or inherent authority

What settlement or dismissal events are recorded in ZS Pharma v. Lupin (1:23-cv-01189)?

Featured-snippet answer: Settlement terms or dismissal status cannot be stated accurately without the docket entries showing the disposition.

Settlement “signals” analysts track

• Joint stipulations of dismissal with prejudice
• Dismissal without prejudice pending refile or appeal
• Confidential agreement statements
• Consent judgments or dismissal conditioned on licensing or timing commitments
• Court docket entries on payment, supply, or launch dates (rarely public)

Key takeaways

• The case identifier “ZS Pharma, Inc. v. Lupin Limited, 1:23-cv-01189” is insufficient to produce an accurate litigation summary, including asserted patents, procedural status, or outcome.
• A complete litigation analysis requires the complaint and subsequent docket orders to identify the RLD/ANDA basis, Paragraph IV posture, asserted patents, claim scope, and any claim construction or dispositive rulings.

FAQs

1. What patents are asserted in ZS Pharma v. Lupin Limited, 1:23-cv-01189?
2. Is ZS Pharma v. Lupin Limited based on an ANDA Paragraph IV certification?
3. Has the district court issued a Markman order in 1:23-cv-01189?
4. Did Lupin file IPRs challenging the asserted patents and did the court stay the case?
5. What was the final disposition of ZS Pharma v. Lupin Limited (settlement, dismissal, or judgment)?

References

1. ZS Pharma, Inc. v. Lupin Limited, No. 1:23-cv-01189 (U.S. District Court docket).